

## PATIENT

NAME: **TEST2 PATIENT** GENDER: **Male**  
 DATE OF BIRTH: **01/31/1998** AGE: **22**

ACCESSION ID: **2007140002**  
 SPECIMEN COLLECTION TIME: **07-13-2020 14:51**  
 SPECIMEN RECEIVED TIME: **07-14-2020 08:51**  
 FINAL REPORT TIME: **07-14-2020 14:51**  
 FASTING: **FASTING**

## PROVIDER

PRACTICE NAME: **Vibrant IT4 Practice**  
 PROVIDER NAME: **Demo Client, DDD (999994)**  
 ADDRESS: **TEST STREET, TEST CITY, KY- 42437.**

**Sample Type: Fingprick**    **Reference Range: <=1.0 Negative; >1.0 Positive**

## SARS-COV-2 ANTIBODY PANEL

ANTIGENS	IgM				IgG			
	Current		Previous		Current		Previous	
<b>Spike Glycoprotein (S1)</b>	0.36	NEGATIVE	0.39	NEGATIVE	1.40	POSITIVE	1.40	POSITIVE
<b>Receptor Binding domain</b>	0.38	NEGATIVE	0.62	NEGATIVE	0.42	NEGATIVE	0.44	NEGATIVE
<b>Spike Glycoprotein (S2)</b>	1.00	NEGATIVE	1.20	POSITIVE	0.91	NEGATIVE	1.50	POSITIVE
<b>Nucleoprotein</b>	0.36	NEGATIVE	0.25	NEGATIVE	0.58	NEGATIVE	0.26	NEGATIVE

### SUMMARY INTERPRETATION

Positive IgG antibodies to Spike Glycoprotein (S1) is indicative of evidence of infection.

This test has been authorized by FDA under an EUA for use by authorized laboratories.

- This test has not been FDA cleared or approved;
- This test has been authorized only for the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens; and
- This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.